视网膜中央静脉阻塞
医学
自然史
眼科
视力
青光眼
黄斑水肿
外科
内科学
作者
Rachel McIntosh,Sophie Rogers,Lyndell L. Lim,Ning Cheung,Jie Jin Wang,Paul Mitchell,Jonathan W. Kowalski,Hiep Nguyen,Tien Yin Wong
出处
期刊:Ophthalmology
[Elsevier BV]
日期:2010-06-01
卷期号:117 (6): 1113-1123.e15
被引量:550
标识
DOI:10.1016/j.ophtha.2010.01.060
摘要
Objective
To describe the natural history of central retinal vein occlusion (CRVO) based on the best available evidence from the literature. Clinical Relevance
Central retinal vein occlusion is a common sight-threatening retinal vascular disease. Despite the introduction of new interventions, the natural history of CRVO is unclear. Methods
Systemic review of all English language articles retrieved using a keyword search of MEDLINE, EMBASE, Current Contents, and the Cochrane Library to November 13, 2008. This was supplemented by hand-searching references of review articles published within the last 5 years. Two investigators independently identified all relevant observational studies evaluating the natural history of RVO and all clinical trials evaluating interventions for CRVO; an untreated control arm was included. Results
Of 5966 citations retrieved, 53 studies were reviewed, providing 3271 eyes with CRVO for analysis of its natural history. Visual acuity (VA) was generally poor at baseline (<20/40) and decreased further over time. Although 6 studies reported an improvement in VA, none of these improvements resulted in VA better than 20/40. Up to 34% of eyes with nonischemic CRVO converted to ischemic CRVO over a 3-year period. In ischemic CRVO cases, neovascular glaucoma developed in at least 23% of eyes within 15 months. In nonischemic CRVO cases, macular edema resolved in approximately 30% of eyes over time, and subsequent neovascular glaucoma was rare. Conclusions
Untreated eyes with CRVO generally had poor VA, which declined further over time. One quarter of eyes with nonischemic CRVO converted to ischemic CRVO. Financial Disclosure(s)
Proprietary or commercial disclosure may be found after the references.
科研通智能强力驱动
Strongly Powered by AbleSci AI